is...(Watching)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HYII UP 50% ON HUGE UPDATE!
$HYII up 50 % !
WOW could be huge IMO !
$HYII HUGE UPDATE OUT
$HYII huge update !
$CEYY huge news out !
$TPNI! NEWS OUT!
$TPNI ON HIGH ALERT! WATCHING FOR ANOTHER RUN LIKE YESTERDAY, BUT TODAY WITH NEWS OUT!!
$TPNI ON HIGH ALERT, NEWS OUT
$TPNI ON HIGH ALERT, NEWS OUT ! WATCHING FOR ANOTHER RUN LIKE YESTERDAY!
$TPNI On High Alert! Hit .29 yesterday on pure momentum, watching what its going to do with news and a huge buzz!!
from these levels hitting .29 again is 70+% !
ALL IMO
$ISCO up 3.4% moving! watching for a push after lunch into the end of the day
$ISCO UP 3.4% watching for a push after lunch
$ISCO ON HIGH ALERT UP 2+% PRE MARKET ! CHECK IT OUT
$ISCO WITH PRE MARKET VOLUME UP 2.47%
$ISCO UP 2+% PRE MARKET !
$ISCO ON YOUR RADAR RIGHT NOW! CHECK OUT LEVEL 2 MOVING UP
$ISCO MOVING UP PRE MARKET ! ON HIGH ALERT !
$ISCO ON HIGH ALERT, LEVEL TWO MOVING UP PRE MARKET !
$ISCO WATCHIGN FOR BREAK OUT TOMORROW!
$ISCO ON HIGH ALERT FOR TOMORROW! ...
ISCO Poster Selected for Presentation at American Association for the Study of Liver Diseases Meeting
The American Association for the Study of Liver Diseases (AASLD) recently highlighted International Stem Cell’s presentation, titled “Human parthenogenetic stem cell-derived hepatocyte transplantation controls serum bilirubin in Gunn rats,” as a Presidential Poster of Distinction at The Liver Meeting during the four-day AASLD’S 64th Annual Meeting in Washington, D.C.
The presentation authors are Dr. Alina Ostrowska, Dr. Larisa Agapova, Tiffany Chu, Dr. Trudy Christiansen-Weber and Dr. Ruslan Semechkin, all of which are from International Stem Cell.
International Stem Cell is a development stage biotech company focused on therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, called parthenogenetic stem cells, created from unfertilized human eggs. In addition to its therapeutic focus, International Stem Cell also provides a growing revenue stream through two wholly owned subsidiaries.
AASLD presented the following information on the company’s liver program:
Background: Extensive studies indicate that pluripotent stem cells are a highly promising alternative source of histocompatible cells for cell replacement therapy. Hepatocyte-like cells (HLCs) derived from human parthenogenetic stem cells (hpSCs) might be transplanted to treat a wide array of metabolic liver diseases including CN1 (Crigler-Najjar syndrome type I). CN1 is the paradigm of inherited liver-based metabolic disorders in that the host liver is lacking one hepatic enzyme – UGT1A1, which is essential for the conjugation and excretion of bilirubin. To obtain ultimate proof that differentiation has been achieved, following the preliminary evaluation in vitro, we tested hepatocyte-like cells in vivo using an accurate animal model of CN1, the Gunn rats which accumulate toxic plasma levels of unconjugated bilirubin.
Methods: Highly enriched populations of definitive endoderm were generated from hpSCs in a novel 3D-differentiation system and then induced to differentiate towards HLCs. The final cells were characterized by using expression profiling including RT-qPCR for dynamic expression of the hepatic lineage genes, immunohistochemistry and FACS analysis to demonstrate hepatocyte-specific markers, drug metabolism assays to determine the activity of CYP450s as well as a luminescent method for measuring UGT activity profile. Production of liver-specific proteins in the culture medium was simultaneously measured by quantitative ELISA. To evaluate engraftment and functional repopulation in vivo, CFSE-labeled hpHC were injected (10×106 per animal) into the spleen of 4-6 week old Gunn rats. Blood serum samples of tested animals were evaluated for indirect bilirubin levels 4, 8 and 19 weeks post-transplantation. Liver tissue samples were embedded in OCT compound and snap frozen, until cryosectioning.
Results: CFSE-labeled HLCs transferred into the spleen were shown to migrate into the liver. Multiple engrafted cells were observed in the periportal regions of the liver lobules and formed morphologically distinct aggregates. The overall liver structure appeared undamaged without signs of inflammation, fibrosis or tumor. Significant decrease and long-term stabilization of bilirubin levels was demonstrated in the serum of tested animals in comparison with sham-treated controls. Although by week 19th serum indirect bilirubin was not normalized in transplanted animals, it resulted in an average 70% reduction compared with pretreatment levels.
Conclusion: This pre-clinical study describes important supportive evidence of the potential efficacy and safety of hpSC-derived hepatocytes which might constitute an easily available source to obtain a large number of transplantable cells for regenerative treatments of CN1. In the long-term, experience with HLCs transplantation for CN1 can be used to develop therapeutic strategies for more common inherited liver diseases.
For more information, visit www.internationalstemcell.com
$ISCO ON RADAR TOMORROW ! WATCHING FOR HUGE BREAK OUT!...
ISCO Poster Selected for Presentation at American Association for the Study of Liver Diseases Meeting
The American Association for the Study of Liver Diseases (AASLD) recently highlighted International Stem Cell’s presentation, titled “Human parthenogenetic stem cell-derived hepatocyte transplantation controls serum bilirubin in Gunn rats,” as a Presidential Poster of Distinction at The Liver Meeting during the four-day AASLD’S 64th Annual Meeting in Washington, D.C.
The presentation authors are Dr. Alina Ostrowska, Dr. Larisa Agapova, Tiffany Chu, Dr. Trudy Christiansen-Weber and Dr. Ruslan Semechkin, all of which are from International Stem Cell.
International Stem Cell is a development stage biotech company focused on therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, called parthenogenetic stem cells, created from unfertilized human eggs. In addition to its therapeutic focus, International Stem Cell also provides a growing revenue stream through two wholly owned subsidiaries.
AASLD presented the following information on the company’s liver program:
Background: Extensive studies indicate that pluripotent stem cells are a highly promising alternative source of histocompatible cells for cell replacement therapy. Hepatocyte-like cells (HLCs) derived from human parthenogenetic stem cells (hpSCs) might be transplanted to treat a wide array of metabolic liver diseases including CN1 (Crigler-Najjar syndrome type I). CN1 is the paradigm of inherited liver-based metabolic disorders in that the host liver is lacking one hepatic enzyme – UGT1A1, which is essential for the conjugation and excretion of bilirubin. To obtain ultimate proof that differentiation has been achieved, following the preliminary evaluation in vitro, we tested hepatocyte-like cells in vivo using an accurate animal model of CN1, the Gunn rats which accumulate toxic plasma levels of unconjugated bilirubin.
Methods: Highly enriched populations of definitive endoderm were generated from hpSCs in a novel 3D-differentiation system and then induced to differentiate towards HLCs. The final cells were characterized by using expression profiling including RT-qPCR for dynamic expression of the hepatic lineage genes, immunohistochemistry and FACS analysis to demonstrate hepatocyte-specific markers, drug metabolism assays to determine the activity of CYP450s as well as a luminescent method for measuring UGT activity profile. Production of liver-specific proteins in the culture medium was simultaneously measured by quantitative ELISA. To evaluate engraftment and functional repopulation in vivo, CFSE-labeled hpHC were injected (10×106 per animal) into the spleen of 4-6 week old Gunn rats. Blood serum samples of tested animals were evaluated for indirect bilirubin levels 4, 8 and 19 weeks post-transplantation. Liver tissue samples were embedded in OCT compound and snap frozen, until cryosectioning.
Results: CFSE-labeled HLCs transferred into the spleen were shown to migrate into the liver. Multiple engrafted cells were observed in the periportal regions of the liver lobules and formed morphologically distinct aggregates. The overall liver structure appeared undamaged without signs of inflammation, fibrosis or tumor. Significant decrease and long-term stabilization of bilirubin levels was demonstrated in the serum of tested animals in comparison with sham-treated controls. Although by week 19th serum indirect bilirubin was not normalized in transplanted animals, it resulted in an average 70% reduction compared with pretreatment levels.
Conclusion: This pre-clinical study describes important supportive evidence of the potential efficacy and safety of hpSC-derived hepatocytes which might constitute an easily available source to obtain a large number of transplantable cells for regenerative treatments of CN1. In the long-term, experience with HLCs transplantation for CN1 can be used to develop therapeutic strategies for more common inherited liver diseases.
For more information, visit www.internationalstemcell.com
BIG BUZZ AROUND IT TONIGHT, ALOT OF EXPOSURE ON FACEBOOK GROUPS AND TWITTER... TOMORROW SHOULD BE AN INTERESTING DAY ! GL AND ALL IMO
$ISCO ON HIGH ALERT! WATCHING FOR A MOVE BACK TO 52WK HIGH OF .41
About International Stem Cell Corp.
International Stem Cell Corp. is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information visit http://www.internationalstemcell.com/
$ISCO On High Alert for tomorrow, watching for a break out
?$ISCO ON HIGH ALERT
ISCO Huge Highlights: Strong 3rd Quarter Revenues and Growth!
Record revenues of $1.67 mill, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 mil per month the corresponding period of 2012.Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
ISCO is Commited To Parkinsons Disease Program!
?
ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
?
? $3.00 Mill of obtained gross proceeds?through a public offering, to be used to fund R&D programs
?
Simon Craw, ISCO's?Executive Vice President of Business Development, stated:?"In July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014."
$ISCO On Radar ...
ISCO Huge Highlights: Strong 3rd Quarter Revenues and Growth!
Record revenues of $1.67 mill, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 mil per month the corresponding period of 2012.Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
ISCO is Commited To Parkinsons Disease Program!
?
ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
?
? $3.00 Mill of obtained gross proceeds?through a public offering, to be used to fund R&D programs
?
Simon Craw, ISCO's?Executive Vice President of Business Development, stated:?"In July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014."
$IOGA ON RADAR RIGHT NOW!
$IOGA ON HIGH ALERT THIS MORNING, WATCHING FOR A STRONG MOVE!
$IOGA ON HIGH ALERT FOR THIS MORNING ! PUT IT ON YOUR RADAR ! WATCHING FOR A STRONG MOVE!
$IOGA ON HIGH ALERT THIS MORNING! WATCHING FOR ANOTHER RALLY HERE ALL IMO
$PLPL watching for a major rally from these keveks, check out chart and see past runs from around these levels... last time we featured it it was a huge winner !
$PLPL on watch for next rally ! On high alert this morning !
$PLPL on high alert this morning !
$PLPL ON CLOSE WATCH FOR A POTENTIAL RALLY FROM HERE !ALL IMO
$PLPL ON HIGH ALERT FOR TOMORROW!
TOMORROW COULD BE A HUGE DAY FOR THE STOCK IMO
$PLPL ON HIGH ALERT FOR TOMORROW! WATCHING FOR A RALLY AGAIN !
$PLPL On high Alert For Tomorrow! We are watching for a major rally here AGAIN!
CEYY #10 on break out boards can it get to #1?
CEYY moving up on break out boards